Dr. Timothy Block Named to the 2011 PharmaVOICE 100 List
Hepatitis B Foundation, Pennsylvania Biotechnology Center and Institute for Hepatitis and Virus Research Co-founder, Volunteer President and Director Receives Life-Science Industry Honor.
- Philadelphia, PA-NJ (1888PressRelease) August 05, 2011 - Dr. Timothy Block, co-founder, volunteer president and director of the Hepatitis B Foundation, the Pennsylvania Biotechnology Center and the Institute for Hepatitis and Virus Research, was recently named to the 2011 PharmaVOICE 100 list for serving as a positive contributor to the life-sciences industry.
"The PharmaVOICE 100 are individuals who think outside the box, pioneer new paths to success, and inspire their colleagues in the industry; they translate industry issues into opportunities and take the time to mentor the next generation of leaders in the life-sciences arena," said Taren Grom, editor-in-chief and co-founder of PharmaVOICE. "We are extremely pleased to recognize these 100 individuals in the July/August issue."
Along with leading the Hepatitis B Foundation, the Pennsylvania Biotechnology Center and the Institute for Hepatitis and Virus Research, Dr. Block heads the Drexel Institute for Biotechnology and Virology Research and is a professor of microbiology and immunology at Drexel University College of Medicine.
Dr. Block's 20-year commitment to hepatitis B research, education and advocacy began in 1991 when he co-founded the Foundation in response to the plight of a local child who was diagnosed with the disease. Since then, he has grown the Foundation into an award-winning nonprofit benefitting millions of hepatitis B sufferers worldwide. In 2003, he founded the Foundation's research institute, the Institute for Hepatitis and Virus Research. In 2006, he spearheaded the creation of the $14 million Pennsylvania Biotechnology Center, which maximizes synergies between nonprofit scientists and their commercial colleagues. Further, under Dr. Block's direction, the Drexel Institute for Biotechnology and Virology Research has been responsible for the creation of six biotechnology companies and engagements with more than 30 regional companies.
The winner of countless community and industry awards, Dr. Block has been responsible for numerous co-discoveries in translational research, co-authored nearly 100 publications and served as the principal investigator for more than $3 million in annual NIH grants.
PharmaVOICE's distinguished honorees are nominated by thousands of magazine readers and then the PharmaVOICE 100 are selected based on comprehensive essays describing how individuals inspired or motivated them or affected positive changes as well as other factors, such as community and philanthropic activities. The honorees represent a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, technology, and many others.
About the Hepatitis B Foundation: The Hepatitis B Foundation, celebrating its 20th anniversary as the global authority dedicated to eliminating hepatitis B, is the only national nonprofit organization solely dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide through research, education and patient advocacy. It is headquartered in the Pennsylvania Biotechnology Center, which it created to accelerate its research mission. To learn more, visit www.hepb.org or call (215) 489-4900.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam